Terfenadine

Terfenadine

Clinical data
Trade names	Seldane, Triludan, Teldane
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a600034
Pregnancy category	US: C (Risk not ruled out)
ATC code	R06AX12 (WHO)
Legal status
Legal status	Withdrawn
Pharmacokinetic data
Protein binding	70%
Elimination half-life	3.5 hours
Identifiers
IUPAC name (RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol
CAS Number	50679-08-8 Y
PubChem CID	5405
IUPHAR/BPS	2608
DrugBank	DB00342 Y
ChemSpider	5212 Y
UNII	7BA5G9Y06Q
KEGG	D00521 Y
ChEMBL	ChEMBL17157 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C32H41NO2
Molar mass	471.673 g/mol
3D model (JSmol)	Interactive image
SMILES OC(c1ccccc1)(c2ccccc2)C4CCN(CCCC(O)c3ccc(cc3)C(C)(C)C)CC4
InChI InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29 (21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/ h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3 N Key:GUGOEEXESWIERI-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Terfenadine
Articles
Most recent articles on Terfenadine Most cited articles on Terfenadine Review articles on Terfenadine Articles on Terfenadine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Terfenadine Images of Terfenadine Photos of Terfenadine Podcasts & MP3s on Terfenadine Videos on Terfenadine
Evidence Based Medicine
Cochrane Collaboration on Terfenadine Bandolier on Terfenadine TRIP on Terfenadine
Clinical Trials
Ongoing Trials on Terfenadine at Clinical Trials.gov Trial results on Terfenadine Clinical Trials on Terfenadine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Terfenadine NICE Guidance on Terfenadine NHS PRODIGY Guidance FDA on Terfenadine CDC on Terfenadine
Books
Books on Terfenadine
News
Terfenadine in the news Be alerted to news on Terfenadine News trends on Terfenadine
Commentary
Blogs on Terfenadine
Definitions
Definitions of Terfenadine
Patient Resources / Community
Patient resources on Terfenadine Discussion groups on Terfenadine Patient Handouts on Terfenadine Directions to Hospitals Treating Terfenadine Risk calculators and risk factors for Terfenadine
Healthcare Provider Resources
Symptoms of Terfenadine Causes & Risk Factors for Terfenadine Diagnostic studies for Terfenadine Treatment of Terfenadine
Continuing Medical Education (CME)
CME Programs on Terfenadine
International
Terfenadine en Espanol Terfenadine en Francais
Business
Terfenadine in the Marketplace Patents on Terfenadine
Experimental / Informatics
List of terms related to Terfenadine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Terfenadine is an antihistamine formerly used for the treatment of allergic conditions. It was brought to market by Hoechst Marion Roussel (now Sanofi-Aventis) and marketed under various brand names, including Seldane in the United States, Triludan in the United Kingdom, and Teldane in Australia. According to its manufacturer, terfenadine had been used by over 100 million patients worldwide as of 1990.It was superseded by fexofenadine in the 1990s due to the risk of a particular type of disruption of the electrical rhythms of the heart (specifically cardiac arrhythmia caused by QT interval prolongation).

Terfenadine is a prodrug, generally completely metabolized to the active form fexofenadine in the liver by the enzyme cytochrome P450 CYP3A4 isoform. Due to its near complete metabolism by the liver immediately after leaving the gut, terfenadine normally is not measurable in the plasma. Terfenadine itself, however, is cardiotoxic at higher doses, while its major active metabolite is not. Terfenadine, in addition to its antihistamine effects, also acts as a potassium channel blocker (Kv11.1 encoded by the gene hERG). Since its active metabolite is not a potassium channel blocker, no cardiotoxicity is associated with fexofenadine.Toxicity is possible after years of continued use with no previous problems as a result of an interaction with other medications such as erythromycin, or foods such as grapefruit. The addition of, or dosage change in, these CYP3A4 inhibitors makes it harder for the body to metabolize and remove terfenadine. In larger plasma concentrations, it may lead to toxic effects on the heart's rhythm (e.g. ventricular tachycardia and torsades de pointes).

History

In the United States, Seldane was brought to market in 1985 as the first nonsedating antihistamine for the treatment of allergic rhinitis.In June 1990, evidence of serious ventricular arrhythmias among those taking Seldane prompted the FDA to issue a report on the risk factors associated with concomitant use of the drug with macrolide antibiotics and ketoconazole.Two months later, the FDA required the manufacturer to send a letter to all physicians, alerting them to the problem; in July 1992, the existing precautions were elevated to a black box warningand the issue attracted mass media attention in reports that people with liver disease or who took ketoconazole, an antifungal agent, or the antibiotic erythromycin, could suffer cardiac arrhythmia if they also took Seldane.

In January 1997, the same month when the U.S. Food and Drug Administration (FDA) had earlier approved a generic version of Seldane made by IVAX Corporation of Miami, the FDA recommended terfenadine-containing drugs be removed from the market and physicians consider alternative medications for their patients.Seldane (and Seldane-D, terfenadine combined with the decongestant pseudoephedrine) were removed from the U.S. market by their manufacturer in late 1997 after the FDA approval of Allegra-D (fexofenadine/pseudoephedrine). >"FDA Approves Allegra-D, Manufacturer To Withdraw Seldane From Marketplace". Food and Drug Administration. Archived from <refs/topics/ANSWERS/ANS00843.html the original on 2008-02-23. Retrieved 2010-11-11.</ref> Terfenadine-containing drugs were subsequently removed from the Canadian market in 1999,

See also

• Ebastine

Synthesis

Terfenadine synthesis:Richardson-Merrell Inc., U.S. Patent 3,878,217 DE 2303305  DE 2303306  DE 2503362  GB 1412605 

External links

• Hoechst Marion Roussel Committed to Education Regarding Seldane Usage, an April 30, 1996 press release